1. COVID-19 in Autoinflammatory Diseases with Immunosuppressive Treatment.
- Author
-
Welzel, Tatjana, Samba, Samuel Dembi, Klein, Reinhild, van den Anker, Johannes N., Kuemmerle-Deschner, Jasmin B., and Demirkaya, Eugen Feist; Eugen Feist; Erkan
- Subjects
COVID-19 ,THERAPEUTICS ,CRYOPYRIN-associated periodic syndromes ,FAMILIAL Mediterranean fever ,COVID-19 pandemic ,AUTOINFLAMMATORY diseases - Abstract
COVID-19 disease increases interleukin (IL)-1β release. Anti-IL-1-treatment is effective in IL-1-mediated autoinflammatory diseases (AID). This case series presents COVID-19 in patients with IL-1-mediated and unclassified AID with immunosuppressive therapy (IT). Patient 1 is a 34-year-old woman with an unclassified AID and methotrexate. Patients 2 and 3 (14-year-old girl and 12-year-old boy, respectively) have a Cryopyrin-Associated Periodic Syndrome (NLRP3 p.Q703K heterozygous, CAPS) treated with canakinumab 150 mg/month since three and five years, respectively. Patient 4 is a 15-year-old girl who has had familial Mediterranean fever (MEFV p.M694V homozygous) for 3 years treated with canakinumab 150 mg/month and colchicine. All patients had a mild acute COVID-19 course, particularly the adolescent patients. A few weeks after COVID-19 recovery, both CAPS patients developed increased AID activity, necessitating anti-IL-1-treatment intensification in one patient. At day 100, one out of four patients (25%) showed positive antibody response to SARS-CoV-2. This is one of the first reports providing follow-up data about COVID-19 in AID. The risk for severe acute COVID-19 disease was mild/moderate, but increased AID activity post-COVID-19 was detected. Follow-up data and data combination are needed to expand understanding of COVID-19 and SARS-CoV-2 immunity in AID and the role of IT. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF